Novavax’s new Covid-19 vaccine could be late to the party

It’s one thing to arrive fashionably late to a party, it’s another to waltz when the last guests stumble through the door.

For Novavax, which on Tuesday took a key step toward U.S. Food and Drug Administration approval of its Covid-19 vaccine, the question is whether there’s much to celebrate for vaccine makers as the Omicron flare fades and vaccination rates decline.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button